Replies to post #43481 on Biotech Values

[DewDiligence]

> DNDN – If no FDA approval next week--the stock gets clocked back to $2. But if it is approved--$10-$14 is probable.<

Let’s clear up one point that is more than just semantics: Provenge is not getting approved or rejected by the FDA next week—the advisory panel is not an arm of the FDA and its function is merely advisory.

The FDA usually, but not always, follows the advice of the advisory panels. The Agency will complete its review of BLA regardless of what happens next week.